BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9934586)

  • 1. Expression of c-erbB-2 oncoprotein in human thyroid tumours.
    Utrilla JC; Martín-Lacave I; San Martín MV; Fernández-Santos JM; Galera-Davidson H
    Histopathology; 1999 Jan; 34(1):60-5. PubMed ID: 9934586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of c-erbB-2 oncoprotein in different types of thyroid tumors: an immunohistochemical study.
    Gumurdulu D; Uguz A; Erdogan S; Tuncer I; Demircan O
    Endocr Res; 2003 Nov; 29(4):465-72. PubMed ID: 14682475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of c-erbB-2 protein in papillary thyroid carcinomas.
    Haugen DR; Akslen LA; Varhaug JE; Lillehaug JR
    Br J Cancer; 1992 Jun; 65(6):832-7. PubMed ID: 1352125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia.
    Sugg SL; Ezzat S; Zheng L; Rosen IB; Freeman JL; Asa SL
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):629-37. PubMed ID: 10197079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue polypeptide antigen in thyroid tumours of follicular cell origin: an immunohistochemical re-evaluation for diagnostic purposes.
    Tuccari G; Barresi G
    Histopathology; 1990 Apr; 16(4):377-81. PubMed ID: 2361653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoblastoma expression in thyroid neoplasms.
    Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
    Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NDRG1 protein overexpression in malignant thyroid neoplasms.
    Gerhard R; Nonogaki S; Fregnani JH; Soares FA; Nagai MA
    Clinics (Sao Paulo); 2010 Jun; 65(8):757-62. PubMed ID: 20835551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her2/neu expression in poorly-differentiated and anaplastic thyroid carcinomas.
    Ensinger C; Prommegger R; Kendler D; Gabriel M; Spizzo G; Mikuz G; Kremser R
    Anticancer Res; 2003; 23(3B):2349-53. PubMed ID: 12894514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma.
    Freudenberg LS; Sheu S; Görges R; Mann K; Bokler S; Frilling A; Schmid KW; Bockisch A; Otterbach F
    Nuklearmedizin; 2005; 44(5):179-82, 184. PubMed ID: 16395492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate-filament expression in thyroid gland carcinomas.
    Schröder S; Dockhorn-Dworniczak B; Kastendieck H; Böcker W; Franke WW
    Virchows Arch A Pathol Anat Histopathol; 1986; 409(6):751-66. PubMed ID: 3094239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of E-cadherin expression in thyroid neoplasms.
    Naito A; Iwase H; Kuzushima T; Nakamura T; Kobayashi S
    J Surg Oncol; 2001 Mar; 76(3):176-80. PubMed ID: 11276021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathological and clinical features of malignant thyroid tumors: classification, immunohistology, prognostic criteria].
    Schröder S
    Veroff Pathol; 1988; 130():1-159. PubMed ID: 3213226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of promyelocytic leukaemia protein in thyroid neoplasms.
    Yu E; Lee KW; Lee HJ
    Histopathology; 2000 Oct; 37(4):302-8. PubMed ID: 11012736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretogranin IV immunoreactivity in medullary thyroid carcinoma: an immunohistochemical study of 62 cases.
    Neuhold N; Ullrich R
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(2):85-9. PubMed ID: 7692664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
    Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
    Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study.
    Kernohan NM; Blessing K; King G; Corbett IP; Miller ID
    J Pathol; 1991 Jan; 163(1):77-80. PubMed ID: 1672154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of metallothionein (MT) and Ki-67 antigen expression in benign and malignant thyroid tumours.
    Królicka A; Kobierzycki C; Puła B; Podhorska-Okołów M; Piotrowska A; Rzeszutko M; Rzeszutko W; Rabczyński J; Domosławski P; Wojtczak B; Dawiskiba J; Dzięgiel P
    Anticancer Res; 2010 Dec; 30(12):4945-9. PubMed ID: 21187474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
    Kremser R; Obrist P; Spizzo G; Erler H; Kendler D; Kemmler G; Mikuz G; Ensinger C
    Virchows Arch; 2003 Apr; 442(4):322-8. PubMed ID: 12715168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
    Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
    Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.